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Abstract: The clinical beneﬁ ts of statins are strongly related to their low density lipoprotein-
cholesterol (LDL-C) lowering properties. However, because mevalonic acid (MVA), the 
product of 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) reductase reaction, 
is the precursor not only of cholesterol but also of nonsteroidal isoprenoid compounds, the 
inhibition of HMG-CoA reductase may result in pleiotropic effects, independent of their 
hypocholesterolemic properties. The discrimination between the pleiotropic from LDL-C 
lowering effects may potentially be more evident during the early phase of treatment since 
plasma MVA levels drop up to 70% within 1–2 hours while a reduction of LDL-C, detectable 
after 24 hours, became signiﬁ cant after 6–7 days. Therefore, the deprivation of circulating 
MVA-derived isoprenoids in the early phase of treatment could be the main mechanism 
responsible for the atheroprotective effect of statins. This early window of protection in the 
absence of LDL-C lowering suggests that the anti-inﬂ ammatory and the pleiotropic properties 
of statins may have clinical importance. Therefore, acute coronary syndromes could represent 
a clinical condition for addressing the early beneﬁ ts of statins therapy, ie, within 24 h of the 
event, independent of LDL-C lowering.
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The clinical beneﬁ ts of 3-hydroxy-3-methyl-3-glutaryl coenzyme A (HMG-CoA) 
reductase inhibitors (statins) are strongly related to their low density lipoprotein-
cholesterol (LDL-C) lowering properties (Baigent et al 2005). However, because 
mevalonic acid (MVA), the product of HMG-CoA reductase reaction, is the precursor 
not only of cholesterol but also of nonsteroidal isoprenoid compounds, the inhibition of 
HMG-CoA reductase may result in pleiotropic effects (Liao and Laufs 2005). Indeed, 
a variety of experimental data indicates that statins can interfere with major events 
involved in the formation of atherosclerotic lesions, independent of their hypocholes-
terolemic properties, including improvement of eNOS activity and anti-inﬂ ammatory 
effects. However, the clinical evidence of these beneﬁ ts still remain to be addressed 
(Liao and Laufs 2005).
Demonstrating the pharmacological properties
of statins beyond LDL-C lowering
How can we demonstrate in a clinical setting the pharmacological properties of statins 
beyond LDL-C lowering? It is well established that the chronic use of statins, in 
coronary heart disease (CHD) patients, is strongly associated with LDL-C lowering 
(Baigent et al 2005). This includes most of the anti-inﬂ ammatory properties, such as 
C reactive protein (CRP) (Kinlay 2007). Therefore it fails to demonstrate the clinical 
relevance of nonLDL effects of statins. Thus, to date, what evidence do we have that 
supports the presence of pleiotropic effects?
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Evidence of pleiotropic effects
The discrimination of the pleiotropic from LDL-C lowering 
effects may potentially be more evident during the early 
phase of treatment, as plasma MVA levels drop up to 70% 
within 1–2 hours after the ﬁ rst administration of statins 
(McTaggart et al 2001) due to a reduction in the liver synthe-
sis of MVA, while a reduction of LDL-C, detectable after 24 
hours (−10%), became signiﬁ cant after 6–7 days (Tobert et al 
1982; Pfohl et al 1998). Inhibition of MVA and isoprenoids 
production may then affect the function of intracellular pro-
teins post-traslationally modiﬁ ed by these isoprenoids, which 
have a half-life time of less than 20–30 hours (Holstein et al 
2002). Among these prenylated proteins, we recall members 
of the Rho, Ras, and Rab families playing a key role in cell 
proliferation, cytoskeleton assembly, platelet activation and 
the generation of oxygen radicals (Corsini 2004; Endres and 
Laufs 2004). It should also be noted that mammalian cells 
do not usually have an intracellular pool of these isopren-
oids that are synthesized only when requested (Corsini et al 
1999). Indeed, a reduction of RhoA prenylation has been 
documented in peripheral blood mononuclear cells isolated 
from a healthy volunteer treated with 40 mg of simvastatin 
(Cicha et al 2004). Therefore, the deprivation of circulating 
MVA-derived isoprenoids in the early phase of treatment 
could be the main mechanism responsible for the atheropro-
tective effect of statins. Indeed, the ARMYDA trial (Patti 
et al 2007) has shown that a 12 hour pretreatment with 40 mg 
of atorvastatin before percutaneous coronary intervention 
improves clinical outcomes in patients with acute coronary 
syndrome (ACS). This early window of protection, during 
which there is a lack of LDL-C lowering, suggests that the 
anti-inﬂ ammatory and pleiotropic properties of statins may 
be of clinical importance.
Since early statin treatment may signiﬁ cantly exacerbate 
the pleiotropic effect, which type of patients could achieve 
potential beneﬁ ts from these pharmacological properties?
Potential benefi ts
Acute clinical conditions represent the potential target pop-
ulation for addressing the early beneﬁ ts of statins therapy; 
ie, within 24 hours of the event. The acute presentation of 
coronary artery disease may involve a complex interac-
tion between the vessel wall, inﬂ ammatory cells, and the 
coagulation cascade (Cannon et al 2005). Indeed, in the 
PROVE-IT trial high dosage of atorvastatin (80 mg) not 
only achieved a better LDL-C reduction as compared with 
40 mg of pravastatin, but strongly lowered CRP: an effect 
that was associated with clinically signiﬁ cant beneﬁ ts in 
acute coronary syndrome (ACS) patients (Cannon et al 
2004). Nevertheless, the initiation of statin therapy in the 
major trials conducted (ie, PROVE-IT and A-to-Z, see 
Cannon et al 2004; de Lemos et al 2004; Wiviott et al 
2006) occurred 4–7 days after the event (Wiviott et al 
2006), thus leaving open the possibility for taking further 
advantage of the pleiotropic effects of statins at the early 
and critical stage in ACS patients. The only study address-
ing the early beneﬁ ts of statin therapy in ACS patients 
was MIRACL (Schwartz et al 2001) where atorvastatin 
was initiated 24 to 96 hours after the event. The results 
show a reduction of recurrent ischemic events in the ﬁ rst 
16 weeks, mostly recurrent symptomatic ischemia requir-
ing hospitalization.
Altogether, it is tempting to speculate that statins may 
indeed interfere with the prenylation process in vivo, leading 
to protective pleiotropic effects independent of LDL-C low-
ering, which may be more relevant after early and intensive 
statin therapy of acute coronary syndromes.
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